Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 14016
Sealed predictions
- TMEM184B in dopamine neurons, braak-0.15 (p 0.705) → -0.66 (p 0.053)receipt 14023
Swarm cases
receipt 14023: TMEM184B in dopamine neurons, braak
- power
- full sample -0.48 (p 0.046, n 18), 95% CI -0.77 to -0.01. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.48 (p 0.045, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.59 (p 0.0096, n 18). not the mix.
- skeptic
- leave-one-out range -0.65 to -0.41, sign flips 0; without severely affected donors -0.48 (p 0.046, n 18). robust.
- cell type
- strongest in OPCs: -0.61 (p 0.0069, n 18) vs -0.48 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TMEM184B in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up TMEM184B · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.43 p 0.131 (needs p < 1.7e-4)
Receipts
loading the receipts